Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Capital Expenditures (2017 - 2025)

Catheter Precision (VTAK) has disclosed Capital Expenditures for 9 consecutive years, with $7000.0 as the latest value for Q2 2025.

  • Quarterly Capital Expenditures fell 89.55% to $7000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $17000.0 through Dec 2025, down 74.63% year-over-year, with the annual reading at $17000.0 for FY2025, 74.63% down from the prior year.
  • Capital Expenditures for Q2 2025 was $7000.0 at Catheter Precision, down from $10000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $239000.0 in Q4 2021, with the low at -$83000.0 in Q3 2021.
  • Average Capital Expenditures over 5 years is $36833.3, with a median of $19000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 4880.0% in 2021, while the deepest fall reached 460.87% in 2021.
  • Over 5 years, Capital Expenditures stood at $239000.0 in 2021, then plummeted by 92.89% to $17000.0 in 2022, then rose by 5.88% to $18000.0 in 2023, then skyrocketed by 272.22% to $67000.0 in 2024, then crashed by 89.55% to $7000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $7000.0, $10000.0, and $67000.0 for Q2 2025, Q1 2025, and Q2 2024 respectively.